Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 48,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Oxytocin, Labor Pain, Induction of Labor Affected Fetus / Newborn, Physiologic Effects of Drugs
Interventions: Electric breast pump, Exogenous oxytocin intravenous infusion without nipple stimulation.; Device · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 933 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 3
States / cities: New Haven, Connecticut • Chicago, Illinois • New York, New York

Conditions: Advanced Solid Tumors, HNSCC, SCLC, NSCLC, TNBC - Triple-Negative Breast Cancer, CRC
Interventions: TUB-030; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 13
States / cities: New Haven, Connecticut • Miami, Florida • Boston, Massachusetts + 9 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Erdafitinib, Magnetic Resonance Imaging; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stress Incontinence Female, Urinary Incontinence, Urinary Incontinence,Stress, Pain, Pain Acute
Interventions: TENS, Control TENS; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Gemcitabine Hydrochloride, Hydrocortisone/Placebo, Vismodegib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 25
States / cities: Beverly Hills, California • Duarte, California • Los Angeles, California + 19 more

Conditions: Chronic Limb Threatening Ischemia
Interventions: Transverse Tibial Bone Transport, TrueLok Elevate; Procedure · Device
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years to 95 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: MISC Intervention, Treatment as Usual
Interventions: MISC intervention, Treatment as Usual (TAU); Behavioral
Lead sponsor: University of Houston; Other
Eligibility: 7 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Injuries
Interventions: Standardized Checklist for Optimizing Procedural Ergonomics in Endoscopy (SCOPE- E) Bundle; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
Interventions: Prevena™ Incision Management System (PIMS), Standard-of-care Dressing; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post Traumatic Stress Disorder, Trauma
Interventions: Beetroot Juice, Placebo Juice; Dietary Supplement
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Plate Waste
Interventions: Food Photography Application©; Device
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 72 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
Interventions: BAY1817080; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Non-Small Cell Lung Cancer
Interventions: Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Aurora, Colorado • Orlando, Florida • Tampa, Florida + 6 more

Conditions: Infants in Neonatal Intensive Care Units
Interventions: Education Plus (E+), Clinical Decision Support, Prescriber Audit and Feedback; Other
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 6,184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 4
States / cities: Wilmington, Delaware • New York, New York • Philadelphia, Pennsylvania

Conditions: Dry Age-related Macular Degeneration
Interventions: GT005; Drug
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more

Conditions: Epilepsy
Interventions: radiosurgery, temporal lobectomy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Cerebral Palsy, Neurologic Disorder, Chromosome Abnormality, Spina Bifida
Interventions: Lite Run Gait Trainer, Usual Treatments; Device · Other
Lead sponsor: Gillette Children's Specialty Healthcare; Other
Eligibility: 4 Years to 17 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Parenting, Adolescent Problem Behavior
Interventions: Parenting Wisely; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 12 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Pawtucket, Rhode Island

Conditions: Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 3
Interventions: UG3NS140720 Deep Brain Stimulation System; Device
Lead sponsor: Gordon H. Baltuch; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Alzheimer Disease
Interventions: [18F] PBR111; Drug
Lead sponsor: Institute for Neurodegenerative Disorders; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Perinatal Hypoxia, Dopamine, Neurobehavioral Manifestations
Interventions: Magnetic Resonance Imaging, Cognitive Performance Testing; Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 8 Years to 15 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Interventions: Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hepatocellular Cancer
Interventions: Sorafenib (SOR), Hydroxychloroquine (HCQ); Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 100 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

The Stimulation To Induce Mothers Study

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.

Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Transverse Tibial Transport for Chronic Limb-Threatening Ischemia (CLTI)

MISC-IPV: A Community-Based Intervention for Children Traumatized by Intimate Partner Violence

Evaluating a Standardized Checklist Bundle for Optimizing Procedural Ergonomics in Endoscopy

The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions

Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD

OSU Plate Waste Study

Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Improving Antimicrobial Prescribing Practices in the Neonatal ICU

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Radiosurgery or Open Surgery for Epilepsy Trial

Post-operative Lite Run Study

Computerized Parenting Intervention

Cerebellar DBS in SCA1 and SCA3 Study

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Measuring Brain Activity of School Age Children

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer